News

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Paula Anne Newman-Casey, MD, MS, explains the multifactorial needs and her decades-long research that resulted in the SEE program for glaucoma patients.

Ophthalmologists report dry eye’s mixed mechanisms, symptom-driven diagnosis, uneven treatment response, and payer hurdles—what needs fixing next.

FDA greenlights first human trial of SVT-001, a regenerative cell therapy aiming to restore vision for patients with rare familial drusen.

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including Medicare coverage limitations, out-of-pocket costs, and the role of assistance programs such as Good Days in expanding treatment access.

Dhoot discusses the full results of the 5-year GALE extension study of pegcetacoplan in patients with GA secondary to age-related macular degeneration.

The planned phase 3 trial will evaluate the triamcinolone acetonide injectable for managing inflammation and pain after cataract surgery.

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss how retina specialists identify appropriate candidates for complement inhibitor therapy in geographic atrophy, set patient expectations, and monitor treatment in real-world clinical practice.

Cases highlight faricimab’s dual VEGF/ANG2 action for severe diabetic macular edema—faster drying, better vision, longer intervals.

Joseph A. Anaya, MD, MBA, and Ashkan M. Abbey, MD, FASRS, FAAO, consider how emerging treatments impact patient vision, functional outcomes, and practical management of geographic atrophy.

University of Utah data show US ophthalmic drug and eye drop shortages last longer and occur more often, affecting local and systemic medications equally.

Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.

The company describes liMeliGhT as a 1-year clinical trial that will support the Biologics License Application (BLA) filing for OCU400 and potential approval in 2027.

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Healthcare staff face splashes, aerosols, chemicals and lasers daily; ANSI-rated eye protection and better compliance prevent most workplace injuries.

Gene and cell therapies plus AI imaging tools accelerate breakthroughs for rare retinal diseases, spotlighting new trials for RP and Stargardt patients.

The clinical study will evaluate a noninvasive corneal strengthening procedure designed to reshape the cornea and correct refractive errors in-office without tissue removal.

Host Deborah Ristvedt, DO, welcomes Trattler to discuss how early inspirations, mentorship, collaboration, and a philosophy of simplifying complex concepts have shaped his ophthalmology career.

A recent nonrandomized trial has demonstrated toric IOLs’ efficacy in providing long-term visual outcomes, reducing amblyopia compared to non-toric lenses.

The FDA has assigned a PDUFA goal date of October 17, 2026.

PULSAR post-hoc finds aflibercept 8 mg matches 2 mg for PCV, offering 12–16-week dosing and reduced injection burden.

A recent study highlights the efficacy of the FAi implant in patients with NIU-related macular edema, improving BCVA and reducing choroidal thickness.

Take a look at some, but certainly not all, that you may have missed from this year’s EnVision Summit.

Study finds low-vision rehab boosts daily function and quality of life, but exposes gaps in long-term data and diverse research.

Interventional therapies give patients faster relief and better vision outcomes

The investigators wanted to assess the safety and feasibility of intravitreal injection of autologous CD34+ bone marrow stem cells (BMSCs) in eyes with vision loss from CRVO.

Real-world nAMD/DME care highlights durable anti-VEGF options and emerging TKIs and gene therapy to cut injection burden, improve vision, and reduce fluid.